Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy
-BRIGHT-SC study passes futility analysis and will continue to completion
-Primary efficacy analysis data expected in second half of 2016
-Feedback from European Medicines Agency incorporated into final study design
HAYWARD, Calif., March 16, 2015 /PRNewswire/ — Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), in collaboration with its partner Zenyaku Kogyo Co., Ltd. today announced that the BRIGHT-SC study of blisibimod in patients with IgA nephropathy (IgAN) should continue to completion as planned. This follows the successful completion of an interim futility analysis, conducted by an independent statistician, which evaluated several important biomarkers of renal disease in patients who had completed at least 8 weeks of treatment.
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.